Using fluorodeoxy-D-glucose-positron emission tomography to monitor neoadjuvant chemotherapy response in sarcoma: A meta-analysis

Table 3 Subgroup analysis based on tumor pathology, patient age groups and chemotherapy regimen

Subgroupcriteria	Characteristics	No. of studies	No. of patients	Se %	P of Se	Sp %	P of Sp	DOR
Tumor pathologya	OS or ES (1-3, 5, 6, 11-15)	10	270	87 (95%CI: 81-92)	> 0.05	91 (95%CI: 84-95)	< 0.05	57.8
	STS (4, 7, 8, 9)	4	55	92 (95%CI: 78-98)		75 (95%CI: 65-83)		47.9
Patient age groupsb	Pediatric patients (1, 2, 13)	3	68	87 (95%CI: 72-96)	> 0.05	90 (95%CI: 73-98)	< 0.01	59.2
	Adult patients (6, 7, 8, 9, 10)	5	135	91 (95%CI: 76-98)		74 (95%CI: 64-82)		25.6
Chemotherapy regimenc	With ifosfamide (2, 6, 7, 9, 10, 12, 14, 15)	8	216	90 (95%CI: 82-95)	> 0.05	70 (95%CI: 61-78)	< 0.01	20.8
	Without ifosfamide (3, 4, 5, 11)	4	139	83 (95%CI: 72-91)		97 (95%CI: 91-100)		103.8

^a[22] not included due to covering both tumor pathology;

^b7 studies not included due to age ranges covering both pediatric and adult patients;

^c3 studies not included [3,20,25] for unclear portion of ifosfamide use. Se: Sensitivity; Sp: Specificity; OS: Osteosarcoma; ES: Ewing sarcoma; DOR: Diagnostic odds ratio.